DK3681885T3 - Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer - Google Patents
Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer Download PDFInfo
- Publication number
- DK3681885T3 DK3681885T3 DK18833127.6T DK18833127T DK3681885T3 DK 3681885 T3 DK3681885 T3 DK 3681885T3 DK 18833127 T DK18833127 T DK 18833127T DK 3681885 T3 DK3681885 T3 DK 3681885T3
- Authority
- DK
- Denmark
- Prior art keywords
- cbp
- imidazo
- tetrahydro
- inhibitors
- quinoline compounds
- Prior art date
Links
- GCGNWZMOENODOJ-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-imidazo[4,5-h]quinoline Chemical class C1C=C2C=CC=NC2=C2C1NCN2 GCGNWZMOENODOJ-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762559436P | 2017-09-15 | 2017-09-15 | |
| US201862692593P | 2018-06-29 | 2018-06-29 | |
| PCT/US2018/051235 WO2019055877A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3681885T3 true DK3681885T3 (da) | 2024-04-15 |
Family
ID=63714164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18833127.6T DK3681885T3 (da) | 2017-09-15 | 2018-09-14 | Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11292791B2 (da) |
| EP (1) | EP3681885B1 (da) |
| AU (1) | AU2018334272B2 (da) |
| CA (1) | CA3075880A1 (da) |
| DK (1) | DK3681885T3 (da) |
| MA (1) | MA50250A (da) |
| TW (2) | TWI846350B (da) |
| WO (2) | WO2019055869A1 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11292791B2 (en) * | 2017-09-15 | 2022-04-05 | Forma Therapeutics, Inc. | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors |
| EP3587418B1 (en) * | 2018-06-29 | 2021-09-01 | Forma Therapeutics, Inc. | Inhibitors of creb binding protein (cbp) |
| IL279734B2 (en) * | 2018-06-29 | 2024-11-01 | Forma Therapeutics Inc | Inhibiting creb binding protein (cbp) |
| US12351577B2 (en) | 2019-03-15 | 2025-07-08 | Forma Therapeutics, Inc. | Inhibiting cyclic AMP-responsive element-binding protein (CREB) |
| AU2020241709B2 (en) * | 2019-03-15 | 2025-12-04 | Forma Therapeutics, Inc. | Compositions and methods for treating androgen receptor positive forms of cancer |
| EP3937936A4 (en) * | 2019-03-15 | 2022-12-28 | Forma Therapeutics, Inc. | INHIBITION OF CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4404207A (en) | 1981-11-06 | 1983-09-13 | Riker Laboratories, Inc. | Antimicrobial 8-substituted benzo [IJ]quinolizines |
| WO1995020589A1 (en) | 1994-01-28 | 1995-08-03 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
| US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
| US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
| JP5355838B2 (ja) | 2000-11-20 | 2013-11-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | キラルな光異性化可能な化合物 |
| WO2003033517A1 (en) | 2001-10-17 | 2003-04-24 | The University Of British Columbia | Ship 1 modulators |
| AU2002349477A1 (en) | 2001-11-26 | 2003-06-10 | Takeda Chemical Industries, Ltd. | Bicyclic derivative, process for producing the same, and use |
| HUP0203976A3 (en) | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| TWI322012B (en) | 2002-12-20 | 2010-03-21 | Organon Nv | Tetrahydroquinoline derivatives |
| IN2003CH00929A (da) | 2003-11-13 | 2008-10-06 | ||
| US20080188527A1 (en) | 2003-12-23 | 2008-08-07 | Cashman John R | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer |
| WO2005099688A2 (en) | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| JP2009520038A (ja) | 2005-12-19 | 2009-05-21 | ジェネンテック・インコーポレーテッド | ピリミジンキナーゼインヒビター |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| CN101489544A (zh) | 2006-05-09 | 2009-07-22 | 海玛奎斯特医药公司 | 治疗血液病的方法 |
| EP1878724A1 (en) | 2006-07-15 | 2008-01-16 | sanofi-aventis | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| CA2574531C (en) | 2007-01-19 | 2016-10-25 | The University Of British Columbia | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
| IN2014MN02330A (da) | 2007-06-21 | 2015-08-14 | Wistar Inst | |
| WO2009000413A1 (en) | 2007-06-26 | 2008-12-31 | Sanofi-Aventis | A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| JP5223864B2 (ja) | 2007-06-27 | 2013-06-26 | 大正製薬株式会社 | １１β−ＨＳＤ１阻害活性を有する化合物 |
| TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| AR072008A1 (es) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 |
| AU2009330686B2 (en) | 2008-06-16 | 2014-07-03 | The Ohio State University Research Foundation | Compounds for the treatment of cancer |
| WO2010110380A1 (ja) | 2009-03-27 | 2010-09-30 | 興和株式会社 | 縮合ピペリジン化合物及びこれを含有する医薬 |
| WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| CN102459271B (zh) | 2009-04-15 | 2014-07-02 | Jw制药公司 | 回折模拟物的新化合物及其制备方法和用途 |
| CN102459248A (zh) | 2009-05-26 | 2012-05-16 | 埃克塞里艾克西斯公司 | 作为PI3K/mTOR抑制剂的苯并氧杂环庚三烯以及它们使用与制造方法 |
| WO2010138490A1 (en) | 2009-05-26 | 2010-12-02 | Exelixis, Inc. | Benzoxazepines as inhibitors of mtor and methods of their use and manufacture |
| US9005670B2 (en) | 2010-01-05 | 2015-04-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| MX2012010115A (es) | 2010-03-01 | 2013-02-26 | Gtx Inc | Compuestos para el tratamiento de cancer. |
| NZ603789A (en) * | 2010-05-26 | 2015-03-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
| US8906943B2 (en) | 2010-08-05 | 2014-12-09 | John R. Cashman | Synthetic compounds and methods to decrease nicotine self-administration |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| EP2678050B1 (en) | 2011-02-24 | 2020-10-14 | Emory University | Noggin blocking compositions for ossification and methods related thereto |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| WO2013148114A1 (en) | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
| US9211333B2 (en) | 2012-06-05 | 2015-12-15 | Hong Kong Baptist University | Anti-cancer agents synthesized based on miliusane compounds |
| IN2015DN02008A (da) | 2012-09-21 | 2015-08-14 | Advinus Therapeutics Ltd | |
| RU2543485C2 (ru) | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| CA2915838C (en) | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Bicyclic bromodomain inhibitors |
| EP3010918B1 (en) | 2013-06-21 | 2018-08-15 | Zenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| AU2014292888B2 (en) | 2013-07-25 | 2018-03-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| DE102013215912B3 (de) | 2013-08-12 | 2015-02-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung |
| AR098414A1 (es) | 2013-11-14 | 2016-05-26 | Bristol Myers Squibb Co | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e |
| CN106029076B (zh) | 2013-11-18 | 2019-06-07 | 福马疗法公司 | 作为bet溴域抑制剂的苯并哌嗪组合物 |
| JP6553632B2 (ja) | 2013-11-18 | 2019-07-31 | フォーマ セラピューティクス，インコーポレイテッド | Ｂｅｔブロモドメイン阻害剤としてのテトラヒドロキノリン組成物 |
| WO2016044694A1 (en) | 2014-09-19 | 2016-03-24 | Genentech, Inc. | Use of cbp/ep300 and bet inhibitors for treatment of cancer |
| US9763922B2 (en) | 2014-11-27 | 2017-09-19 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| EP3242878B1 (en) | 2015-01-08 | 2020-10-14 | Impetis Biosciences Ltd. | Bicyclic compounds, compositions and medicinal applications thereof |
| WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| AU2017263574B2 (en) | 2016-05-12 | 2022-11-17 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
| MA45122A (fr) | 2016-05-24 | 2019-04-10 | Constellation Pharmaceuticals Inc | Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617627D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| US11292791B2 (en) * | 2017-09-15 | 2022-04-05 | Forma Therapeutics, Inc. | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors |
| US11801243B2 (en) * | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
-
2018
- 2018-09-14 US US16/647,478 patent/US11292791B2/en active Active
- 2018-09-14 WO PCT/US2018/051214 patent/WO2019055869A1/en not_active Ceased
- 2018-09-14 MA MA050250A patent/MA50250A/fr unknown
- 2018-09-14 AU AU2018334272A patent/AU2018334272B2/en active Active
- 2018-09-14 TW TW112106967A patent/TWI846350B/zh active
- 2018-09-14 TW TW107132421A patent/TWI795440B/zh active
- 2018-09-14 DK DK18833127.6T patent/DK3681885T3/da active
- 2018-09-14 WO PCT/US2018/051235 patent/WO2019055877A1/en not_active Ceased
- 2018-09-14 CA CA3075880A patent/CA3075880A1/en active Pending
- 2018-09-14 EP EP18833127.6A patent/EP3681885B1/en active Active
-
2022
- 2022-02-10 US US17/669,135 patent/US11787803B2/en active Active
-
2023
- 2023-09-08 US US18/463,587 patent/US20240150349A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3681885A1 (en) | 2020-07-22 |
| MA50250A (fr) | 2020-07-22 |
| TW201920169A (zh) | 2019-06-01 |
| AU2018334272A1 (en) | 2020-04-16 |
| TW202340191A (zh) | 2023-10-16 |
| TWI846350B (zh) | 2024-06-21 |
| US20240150349A1 (en) | 2024-05-09 |
| US20220169647A1 (en) | 2022-06-02 |
| US20200216445A1 (en) | 2020-07-09 |
| WO2019055877A1 (en) | 2019-03-21 |
| CA3075880A1 (en) | 2019-03-21 |
| US11787803B2 (en) | 2023-10-17 |
| EP3681885B1 (en) | 2024-02-28 |
| AU2018334272B2 (en) | 2023-06-15 |
| US11292791B2 (en) | 2022-04-05 |
| TWI795440B (zh) | 2023-03-11 |
| WO2019055869A1 (en) | 2019-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2024003I2 (el) | Ενωσεις χρησιμες ως αναστολεις κινασης | |
| CY1125826T1 (el) | Ενωσεις αναστολεις της βητα-λακταμασης | |
| DK3697785T3 (da) | Imidazo-pyridine forbindelser som pad-inhibitorer | |
| DK3728252T3 (da) | 4-azaindolforbindelser | |
| DK3684767T3 (da) | Heterocykliske forbindelser som pad-inhibitorer | |
| IL269216A (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| DK3442980T3 (da) | Heterocykliske forbindelser som ret-kinase-hæmmere | |
| DK3656769T3 (da) | Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor | |
| DK3277677T3 (da) | 1-cyano-pyrrolidinforbindelser som usp30-hæmmere | |
| DK3371190T3 (da) | Heterocykliske forbindelser som pi3k-gamma-inhibitorer | |
| DK3436461T3 (da) | Pyrrolotriazinforbindelser som tam-inhibitorer | |
| DK3365334T3 (da) | Benzolactamforbindelser som proteinkinaseinhibitorer | |
| DK3681885T3 (da) | Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer | |
| DK3472167T3 (da) | Heterocykliske forbindelser som immunomodulatorer | |
| DK3580220T3 (da) | Aminotriazolpyridiner som kinasehæmmere | |
| DK3377488T3 (da) | Heterocykliske forbindelser som immunomodulatorer | |
| DK3303348T3 (da) | Naphthyridinforbindelser som JAK-kinaseinhibitorer | |
| DK3298002T3 (da) | Heterocykliske amider som kinasehæmmere | |
| PL3209656T3 (pl) | Związki indolo-karboksyamidu użyteczne jako inhibitory kinazy | |
| DK3717488T3 (da) | Substituerede furanopyrimidinforbindelser som pde1-inhibitorer | |
| EP3609871A4 (en) | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | |
| DK3762368T3 (da) | Aminopyrazindiolforbindelser som pi3k-y-inhibitorer | |
| DK3582780T3 (da) | Aminopyrimidinforbindelser, der er anvendelige som SSAO-inhibitorer | |
| DK3638680T3 (da) | Heteroaromatiske forbindelser som vanininhibitorer | |
| DK3288944T3 (da) | Imidazopyrazinoner som pde1-inhibitorer |